Source: Lung Science Conference 2009 - Cell proliferation, Differentiation and Carcinogenesis



Rating:

Share or cite this content

Citations should be made in the following way:
I. Irminger-Finger, L. Li, F. Molica, J.-C. Pache, G. Laurent, A. Bianco (Geneva, Switzerland). Oral presentation: Truncated isoforms of BRCA1-associated protein BARD1 are expressed in NSCLC and are potential targets for treatment. Lung Science Conference 2009 - Cell proliferation, Differentiation and Carcinogenesis

Member's Comments

No comment yet.

Related content which might interest you: Truncated isoforms of BRCA1-associated protein BARD1 are expressed in NSCLC and are potential targets for treatment Source: Annual Congress 2009 - Basic science and lung cancer Year: 2009 Distinct BARD1 isoforms expressed in lung cancer potential targets for treatment Source: Annual Congress 2008 - Novel targets in the molecular pathology of lung cancer and COPD Year: 2008 Cancer-associated oncogenic BARD1 isoforms: From biomarker expression studies to development of a blood test for early detection of lung cancer Source: Annual Congress 2012 - Early detection of lung cancer Year: 2012 Nuclear expression of Y-Box binding protein (YB-1) as a negative prognostic marker in non-small cell lung cancer Source: Annual Congress 2003 - Lung cancer biology Year: 2003 Distinct forms of BARD1 expressed in lung fibrosis and lung cancer Source: Eur Respir J 2006; 28: Suppl. 50, 325s Year: 2006 The prognostic value of altered pRb and p53 protein expression in non-small cell lung cancer Source: Eur Respir J 2003; 22: Suppl. 45, 363s Year: 2003 Radiation/cisplatin/vinorelbine therapy increase p53 protein phosphorylated at serine 392 in recurrent primary squamous cell lung cancer Source: Eur Respir J 2001; 18: Suppl. 33, 17s Year: 2001 Overexpression of inhibitor of DNA-binding proteins and angiogenic markers have higher impact on survival of non small cell lung cancer patients Source: Annual Congress 2012 - New insights in the pathology of lung cancer Year: 2012 Polymorphisms A1026G and G369C of CDKN1A/p21 and p53 genes in lung cancer Source: Annual Congress 2011 - Lung cancer: molecular pathology and functional genomics Year: 2011 XAGE-1b and p53: Potential targets for immunotherapy of non-small cell lung cancer (NSCLC) Source: Annual Congress 2012 - Treatment of lung cancer Year: 2012 Nuclear YB-1 expression as a negative prognostic marker in nonsmall cell lung cancer Source: Eur Respir J 2004; 23: 14-19 Year: 2004 Characteristics and prognostic relevance of p53 gene mutations in Polish non small cell lung cancer (NSCLC) patients Source: Eur Respir J 2005; 26: Suppl. 49, 92s Year: 2005 Expression of survivin and p53 protein in pulmonary tumours Source: Annual Congress 2011 - Progress in pathology of lung cancer Year: 2011 A new KIF5B–ERBB4 gene fusion in a lung adenocarcinoma patient Source: ERJ Open Res, 7 (1) 00582-2020; 10.1183/23120541.00582-2020 Year: 2021 MDM2 gene amplification and mdm2 protein expression in NSCLC cells Source: Eur Respir J 2005; 26: Suppl. 49, 91s Year: 2005 Activation of NRF2 is responsible for the overexpression of peroxiredoxin and sulphiredoxin in human lung cancer Source: Annual Congress 2009 - Biological and clinical markers in lung cancer Year: 2009 Cyclooxygenase(COX)-2 is over-expressed in non small cell lung cancer (NSCLC) and is a potential target for treatment Source: Eur Respir J 2002; 20: Suppl. 38, 400s Year: 2002 Loss of orphan G protein coupled receptor GPRC5A is associated with metastatic disease and poor survival in patients with adenocarcinomas of the lung Source: Annual Congress 2011 - Lung cancer: molecular pathology and functional genomics Year: 2011 Combined expression of p53, Bcl-2 and p21WAF-1 proteins in endobronchial biopsies may be associated with lung cancer prognosis Source: Eur Respir J 2001; 18: Suppl. 33, 230s Year: 2001 p53 and mdm2 expression in nonsmall cell lung cancer (NSCLC): the lack of prognostic relevance Source: Eur Respir J 2001; 18: Suppl. 33, 230s Year: 2001